Michael Goettler | Global President
Pfizer Rare Disease

Michael Goettler, Global President, Pfizer Rare Disease

Michael currently is the Global President, Rare Diseases for Pfizer’s Innovative Health Business.
 
Michael has a broad and international background in general management, sales, marketing, business development, new product planning and eBusiness. Michael has lived and worked in Germany, USA, Japan, Korea, France and Italy. He is fluent in English, German and French with a basic knowledge of Japanese and Korean.
 
Michael began his career working at Hoechst in Germany, where he quickly moved into roles of increasing responsibility, including Executive Vice President CEO of Hoechst Marion Roussel Korea. In 1999, Michael moved to the US and had a variety of global roles at Aventis Pharma, including business development, eBusiness and global marketing. From 2001 to 2002, Michael led the global launch of Lantus (insulin glargine), which today is the leading insulin brand with global sales of over $7B. In 2002, Michael moved to Japan as head of the Diabetes business unit. In 2005, after the acquisition of Aventis by Sanofi, Michael took responsibility for marketing of the full portfolio of products. Under his leadership Sanofi launch Plavix, currently the largest pharmaceutical brand in Japan.
 
In 2007, Michael joined Wyeth in the US as Vice President, New Business and Global Business Manager for BMP-2 for the BioPharma BU. He later became Vice President, U.S. Marketing for Relistor, before assuming the position as President of Wyeth in Japan.
 
After the integration of Pfizer and Wyeth, Michael was appointed as Regional President Asia­ Pacific for Specialty Care, a position he held until June 2012. From June 2012 December 2013 Michael was the Regional President, Europe for Pfizer Specialty Care and the chair of the European Management Team, with direct responsibility for $5.2B in revenue and approximately 1900 employees. He was also the chair of the European Management Team.
 
For 2014 and 2015, Michael was the Global Commercial Officer, Senior Vice President for Pfizer’s Global Innovative Pharma Business.
 
Michael, a native German, studied in Germany, France and the US. He holds an M.B.A. from the University of Texas at Austin and graduated from the Koblenz School of Corporate Management in Germany, both with summa cum laude.
 
Michael is a member of the board of directors of PSI (Population Services International), a global health organization dedicated to improving the health of people in the developing world by focusing on serious challenges like a lack of family planning, HIV and AIDS, barriers to maternal health, and the greatest threats to children under five, including malaria, diarrhea, pneumonia and malnutrition.
 
 

back to speakers